Loading
Every dated change on the records linked to MET exon 14 and MET-amplified non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Response rate 68% (treatment-naive, n=28) and 41% (previously treated, n=69) in MET exon 14 skipping disease; about a third in high-level MET amplification.
Independent-review objective response 46% (95% CI 36 to 57) among 99 patients with at least nine months of follow-up; median duration of response 11.
A milestone in how this cancer is treated.